Literature DB >> 11226291

Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice.

P Meneton1, M Bloch-Faure, A A Hagege, H Ruetten, W Huang, S Bergaya, D Ceiler, D Gehring, I Martins, G Salmon, C M Boulanger, J Nussberger, B Crozatier, J M Gasc, D Heudes, P Bruneval, T Doetschman, J Ménard, F Alhenc-Gelas.   

Abstract

Tissue kallikrein is a serine protease thought to be involved in the generation of bioactive peptide kinins in many organs like the kidneys, colon, salivary glands, pancreas, and blood vessels. Low renal synthesis and urinary excretion of tissue kallikrein have been repeatedly linked to hypertension in animals and humans, but the exact role of the protease in cardiovascular function has not been established largely because of the lack of specific inhibitors. This study demonstrates that mice lacking tissue kallikrein are unable to generate significant levels of kinins in most tissues and develop cardiovascular abnormalities early in adulthood despite normal blood pressure. The heart exhibits septum and posterior wall thinning and a tendency to dilatation resulting in reduced left ventricular mass. Cardiac function estimated in vivo and in vitro is decreased both under basal conditions and in response to beta-adrenergic stimulation. Furthermore, flow-induced vasodilatation is impaired in isolated perfused carotid arteries, which express, like the heart, low levels of the protease. These data show that tissue kallikrein is the main kinin-generating enzyme in vivo and that a functional kallikrein-kinin system is necessary for normal cardiac and arterial function in the mouse. They suggest that the kallikrein-kinin system could be involved in the development or progression of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226291      PMCID: PMC30190          DOI: 10.1073/pnas.051619598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  Stress pathways and heart failure.

Authors:  K R Chien
Journal:  Cell       Date:  1999-09-03       Impact factor: 41.582

2.  Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors.

Authors:  J B Pesquero; R C Araujo; P A Heppenstall; C L Stucky; J A Silva; T Walther; S M Oliveira; J L Pesquero; A C Paiva; J B Calixto; G R Lewin; M Bader
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene.

Authors:  J A Silva; R C Araujo; O Baltatu; S M Oliveira; C Tschöpe; E Fink; S Hoffmann; R Plehm; K X Chai; L Chao; J Chao; D Ganten; J B Pesquero; M Bader
Journal:  FASEB J       Date:  2000-10       Impact factor: 5.191

4.  Transgenic mouse model of stunned myocardium.

Authors:  A M Murphy; H Kögler; D Georgakopoulos; J L McDonough; D A Kass; J E Van Eyk; E Marbán
Journal:  Science       Date:  2000-01-21       Impact factor: 47.728

5.  Altered urinary kallikrein excretion in human hypertension.

Authors:  H S Margolis; R Geller; J J Pisano; A Sjoerdsma
Journal:  Lancet       Date:  1971-11-13       Impact factor: 79.321

6.  Kinins released from horse heat-acid-denaturated plasma by plasmin, plasma kallikrein, trypsin and Bothrops kininogenase.

Authors:  E Gapanhuk; O B Henriques
Journal:  Biochem Pharmacol       Date:  1970-06       Impact factor: 5.858

7.  Propofol-induced modifications of cardiomyocyte calcium transient and sarcoplasmic reticulum function in rats.

Authors:  T Guenoun; O Montagne; M Laplace; B Crozatier
Journal:  Anesthesiology       Date:  2000-02       Impact factor: 7.892

8.  Can cellular transplantation improve function in doxorubicin-induced heart failure?

Authors:  M Scorsin; A A Hagege; I Dolizy; F Marotte; N Mirochnik; H Copin; M Barnoux; M le Bert; J L Samuel; L Rappaport; P Menasché
Journal:  Circulation       Date:  1998-11-10       Impact factor: 29.690

9.  Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group.

Authors:  L Mestroni; C Rocco; D Gregori; G Sinagra; A Di Lenarda; S Miocic; M Vatta; B Pinamonti; F Muntoni; A L Caforio; W J McKenna; A Falaschi; M Giacca
Journal:  J Am Coll Cardiol       Date:  1999-07       Impact factor: 24.094

10.  Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice.

Authors:  C Emanueli; R Maestri; D Corradi; R Marchione; A Minasi; M G Tozzi; M B Salis; S Straino; M C Capogrossi; G Olivetti; P Madeddu
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

View more
  31 in total

1.  Endothelial AT(2)-receptors: chicken or egg?

Authors:  Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

2.  Vascular remodeling and the kallikrein-kinin system.

Authors:  Oscar A Carretero
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 3.  A new look at electrolyte transport in the distal tubule.

Authors:  Dominique Eladari; Régine Chambrey; Janos Peti-Peterdi
Journal:  Annu Rev Physiol       Date:  2011-09-02       Impact factor: 19.318

Review 4.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

5.  Tissue kallikrein permits early renal adaptation to potassium load.

Authors:  Soumaya El Moghrabi; Pascal Houillier; Nicolas Picard; Fabien Sohet; Bharath Wootla; May Bloch-Faure; Françoise Leviel; Lydie Cheval; Sebastian Frische; Pierre Meneton; Dominique Eladari; Régine Chambrey
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

Review 6.  Regulation of transport in the connecting tubule and cortical collecting duct.

Authors:  Alexander Staruschenko
Journal:  Compr Physiol       Date:  2012-04       Impact factor: 9.090

Review 7.  Kallikrein-kinin in stem cell therapy.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

8.  Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse.

Authors:  W Huang; Y Gallois; N Bouby; P Bruneval; D Heudes; M F Belair; J H Krege; P Meneton; M Marre; O Smithies; F Alhenc-Gelas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

9.  Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans.

Authors:  Michel Azizi; Pierre Boutouyrie; Alvine Bissery; Mohsen Agharazii; Francis Verbeke; Nora Stern; Alessandra Bura-Rivière; Stéphane Laurent; François Alhenc-Gelas; Xavier Jeunemaitre
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

10.  Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells.

Authors:  Sinisa Stanisavljevic; Tatjana Ignjatovic; Peter A Deddish; Viktor Brovkovych; Kai Zhang; Ervin G Erdös; Randal A Skidgel
Journal:  J Pharmacol Exp Ther       Date:  2005-11-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.